Amgen heart failure drug approved by US FDA
Amgen Inc’s Corlanor with treats people suffering from health failure has been approved by health regulators.
This gives the world’s largest biotechnology company its first cardiovascular medicine product.
The Food and Drug Administration said it approved the use of Corlanor (ivabradine) on top of current standard of care beta blockers, for patients with moderate to severe heart failure and a resting heart rate of at least 70 beats per minute.
Amgen acquired U.S. commercial rights to Corlanor from French drugmaker Servier, which sells the medicine in Europe.
Category: Features, Pharmaceuticals
